Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $82,260.20 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Krishnan Viswanadhan sold 2,959 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the transaction, the insider owned 5,141 shares in the company, valued at approximately $142,919.80. This trade represents a 36.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Agios Pharmaceuticals Stock Down 0.7%

Shares of AGIO stock opened at $28.07 on Thursday. The firm has a 50 day moving average price of $28.12 and a two-hundred day moving average price of $33.04. The company has a market capitalization of $1.64 billion, a PE ratio of -3.95 and a beta of 0.89. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on AGIO shares. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Bank of America lifted their price objective on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Royal Bank Of Canada downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $57.00 to $28.00 in a report on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, December 29th. Finally, The Goldman Sachs Group cut their price target on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research note on Thursday, November 20th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $40.67.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AGIO. Wellington Management Group LLP boosted its stake in shares of Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after purchasing an additional 2,049,287 shares in the last quarter. MPM Bioimpact LLC acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth $35,478,000. State Street Corp grew its position in Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after acquiring an additional 845,433 shares during the last quarter. TCG Crossover Management LLC increased its holdings in Agios Pharmaceuticals by 105.2% in the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after purchasing an additional 733,038 shares in the last quarter. Finally, Capital International Investors bought a new position in Agios Pharmaceuticals in the fourth quarter valued at about $19,159,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.